Compare Enveric Biosciences Inc (ENVB) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs UnitedHealth Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while UnitedHealth Group Inc trades at $424.88 (market cap $380.08B). The key difference: UnitedHealth Group Inc is far larger — about 71443.6× Enveric Biosciences Inc's market cap, and UnitedHealth Group Inc pays a 2.22% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | UNH | |
|---|---|---|
Market Cap | $5.32M | $380.08B |
Sector | Health | Health |
52-Week High | $17.40 | $431.68 |
52-Week Low | $1.28 | $237.77 |
Enterprise Value | $408.82K | $426.76B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
UnitedHealth Group (UNH) trades at $425.19, down 0.91% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growth to $447.57B in 2025 and consistent earnings beats, though net margins have compressed. Recent news highlights strategic moves to reduce pediatric prior authorizations, aiming to improve care access and operational efficiency.
Outlook remains positive with an 82.69% analyst buy rating and $438.33 consensus target, but risks include regulatory lawsuits and debt levels. The aging U.S. population and tech investments provide growth tailwinds, yet investors should monitor margin pressures and legal challenges from state Medicaid suits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
